11 Specific Facts About HRT and Bone Protection That Go Beyond 'Take Calcium'
The word 'osteoporosis' used to feel like something that happened to other people — smaller, older, frailer women. Then a DEXA scan came back with numbers that were heading in the wrong direction, and suddenly it felt very personal. What was frustrating wasn't the result — it was realising how much of the estrogen-bone connection had never been mentioned, even by good doctors. That gap is exactly what this page is trying to close.
Learn more about Rose →Estrogen is the primary regulator of bone turnover in women — not calcium
Bone is living tissue that is constantly being broken down by cells called osteoclasts and rebuilt by osteoblasts. Estrogen suppresses osteoclast activity, meaning its decline at menopause tips the balance sharply toward bone loss — a process that calcium alone cannot stop because calcium is a building material, not a regulator. Without adequate estrogen signalling, the remodelling cycle simply runs too fast for any supplement to compensate.
Bone loss accelerates dramatically in the two years around the final period
Studies using serial DEXA scans show that women can lose between 10 and 20 percent of their spine bone density in the five years bracketing the final menstrual period, with the steepest decline occurring in the two years closest to it. This window is far more consequential than the slow attrition of later postmenopause. Catching this phase with HRT is therefore meaningfully different — in timing terms — from starting it a decade later.
The Women's Health Initiative confirmed HRT cuts hip fracture risk by roughly 33 percent
The WHI randomised controlled trial — the largest of its kind — found that combined estrogen-progestogen therapy reduced hip fracture incidence by approximately 33 percent compared to placebo, and vertebral fractures by a similar margin. This is a clinically meaningful reduction in the fractures that cause the most disability and mortality in older women. The fracture data from the WHI are often overshadowed by the headline breast cancer findings, but they represent some of the strongest evidence for any preventive intervention in this age group.
Estrogen-only HRT shows an even stronger bone signal than combined therapy
In the estrogen-alone arm of the WHI — which enrolled women who had had a hysterectomy — hip fracture reduction reached around 39 percent, slightly stronger than the combined arm. This matters because it separates the bone-protective effect cleanly as an estrogen effect, with progestogen added only for uterine protection in women who still have a uterus. Women without a uterus receive the bone benefit with a simpler hormonal regimen.
The bone benefit disappears relatively quickly once HRT is stopped
Long-term follow-up studies from the WHI and Scandinavian cohorts show that the fracture-protective advantage conferred by HRT largely dissipates within a few years of stopping, because bone turnover accelerates again once estrogen is withdrawn. This is a practical consideration that is rarely discussed at prescription: the timing and duration of HRT use affects how much long-term skeletal benefit is retained. Women who stop HRT in their mid-50s and live into their 80s may not carry significant residual protection through their highest-fracture-risk decades.
Transdermal estrogen reaches bone tissue just as effectively as oral forms
Patches, gels, and sprays deliver estradiol transdermally, bypassing first-pass liver metabolism, and the evidence shows bone density outcomes are equivalent to oral estrogen at comparable doses. Transdermal routes have additional cardiovascular and clotting advantages, and for women who prefer them for those reasons, there is no bone-protection trade-off. This matters because some women are told — incorrectly — that patches are 'weaker' than tablets.
Lower doses of estrogen still provide meaningful bone protection
Studies have demonstrated that even half-standard or ultra-low doses of estradiol — doses sometimes used to manage symptoms with a gentler profile — produce statistically significant bone density preservation compared to placebo. This is important for women who are on low-dose HRT primarily for symptom relief, because they are likely receiving incidental skeletal benefit. However, the fracture endpoint data are less complete at ultra-low doses, so the magnitude of protection is less precisely quantified.
DEXA scanning before and during HRT gives a concrete measure of individual response
Not all women respond to HRT with the same magnitude of bone density gain or stabilisation, and a baseline DEXA scan followed by a repeat after two to three years of therapy provides an objective picture of whether the treatment is working for that individual. This is particularly relevant for women with pre-existing low bone density or additional risk factors such as low body weight, smoking history, or a family history of hip fracture. DEXA is underused as a monitoring tool alongside HRT, despite being inexpensive and providing actionable data.
Early surgical menopause carries a higher fracture risk than natural menopause — and HRT closes that gap
Women who have both ovaries removed before the age of natural menopause lose estrogen abruptly and earlier than their peers, and long-term studies show they have significantly higher rates of osteoporotic fracture if they do not use HRT. The evidence for HRT being particularly important in this group — at least until the average age of natural menopause — is among the most consistent in the field. For these women, the bone argument for HRT is especially strong, independent of symptom burden.
Progesterone itself may have an independent, modest bone-building effect
There is emerging evidence — primarily from cell studies and smaller human trials — that progesterone receptors on osteoblasts are active, and that progesterone may stimulate bone formation to a small degree independently of estrogen. Micronised progesterone (the bioidentical form) has been the subject of most of this research. The effect size appears modest and the evidence is not yet at the level of large RCTs, but it adds nuance to the idea that the progestogen component of combined HRT is purely a uterine safety measure.
HRT and bisphosphonates can be used together for women with established low bone density
For women who already have osteoporosis or significantly low bone density at the time of menopause, HRT alone may not be sufficient and combination with bisphosphonate therapy (such as alendronate) may be appropriate — a strategy supported by evidence showing additive effects on bone density. This is not widely discussed because the two treatment categories tend to be siloed in different clinical specialities. Women navigating both a menopause diagnosis and low DEXA scores benefit from knowing these approaches are not mutually exclusive and that the conversation should ideally involve both a menopause specialist and a bone health clinician.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.